The PI3K/AKT signaling can also inhibit the lysosome-mediated degradation of NOTCH1 [19] a new key cancer gene in CLL whose genetic and pathway alterations are likely to represent a novel oncogenic process in this disease [20,21,22,23]. This evidence concerns the gene PIK3CD and B-cell chronic lymphocytic leukemia.